Thiophene derivatives as Sphingosine-1-phosphate-1 receptor...

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C549S060000, C514S365000

Reexamination Certificate

active

07605269

ABSTRACT:
The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

REFERENCES:
patent: 6156787 (2000-12-01), Broughton et al.
patent: 2008/0176926 (2008-07-01), Bolli
patent: 2008/0194670 (2008-08-01), Bolli
patent: 2008/0257352 (2008-10-01), Penton
patent: 2008/0300294 (2008-12-01), Bolli
patent: 2008/0318955 (2008-12-01), Bolli
patent: 2009/0005421 (2009-01-01), Bolli
patent: WO-91/15583 (1991-10-01), None
patent: WO 99/46277 (1999-09-01), None
patent: WO 2003/062248 (2003-07-01), None
patent: WO-03/105771 (2003-12-01), None
patent: WO 2003/105771 (2003-12-01), None
patent: WO-2004/035538 (2004-04-01), None
patent: WO 2004/103279 (2004-12-01), None
patent: WO-2004/103279 (2004-12-01), None
patent: WO-2006/010379 (2006-02-01), None
patent: WO 2006/010544 (2006-02-01), None
Dubus et al. (Ann. Chim., 1975, vol. 10; p. 331-336.
T. Hla, et al., T.J. “An Abundant Transcript Induced in Differentiating Human Endothelial Cells Encodes a Polypeptide with Structural Similiarities to G-protein-coupled Receptors,” Biol Chem, 265 (1990), pp. 9308-9313.
Philip L. Gould, “Salt selection for basic drugs,” Int. J. Pharm., (1986), 33, pp. 201-217.
A.R. Gangloff, et al., “Synthesis of 3,5-disubstituted-1,2,4-oxadiazoles using tetrabutylammonium fluoride as a mild and efficient catalyst,” Tetrahedron Lett, 42 (2001), pp. 1441-1443.
T. Suzuki, et al., “Synthesis of the Selective 5-Hydroxytryptamine 4 (5-HT)4) Receptor Agonist (+)-(s)-2-Chloro-5-methoxy-4-[2-piperidylmethyl)-1,2,4-oxadiaol-3-yl]aniline” Chem. Pharm. Bull., 47 (1999), pp. 120-122.
R.F. Poulain, et al., “Parallel synthesis of 1,2,4-oxadiazoles from carboxylic acides using an imroved, uronium-based, activation,” Tetrahedron Lett., 42 (2001), pp. 1495-1498.
R.M. Srivastava, et al., “Synthesis of 3-aryl-5-[thien-3-YL methtyl]-1.2.4-oxadiazoles,” Synthetic Commun. 29 (1999), pp. 1437-1450.
E.O. John, et al., “Reaction of (Difluoroamino) difluoroacetonitrile and (Difluoroamino) difluoroacetamidoxime,” Inorganic Chemisry, 27 (1988), pp. 3100-3104.
B. Kaboudin, et al., “One-pot synthesis of 1,2,4-oxadiazoles mediated by microwave irradiation under solvent-free condition,” Heterocycles 60 (2003), pp. 2287-2292.
A. Hamze, et al., J. Sythesis of a Various 3-Substitued 1,2,4-Oxadiazole-Contraining Chiral β3- and α-Amino Acids from Fmoc-Protected Aspartic Acid, J. Org. Chem. 68 (2003), pp. 7316-7321.
J. Cui, et al., “Design and Synthesis of Highly Constrained Factor Xa Inhibitors: Amidine-Substituted Bis(benzoyl)-[1,3]-diazepan-2-ones and Bis(benzylidene)-bis (gemdimethyl)cycloketones,” Bioorg. Med. Chem. 11 (2003), pp. 3379-3392.
T.W. Greene, et al., “Protective Groups in Organic Synthesis,” 3rd Edition, Wiley New York, 1991.
P.J. Kocienski, Protecting Group, Thieme Stuttgart, 1994.
C. D. Bedford et al., “Nonquaternary Cholinesterase Reactivators. 3. (3(5)-Substituted 1,2,4-Oxadiaxo1-5(3)-aldoximes and 1,2,4-Oxadiazole-5(3)-thiocarbohydroximates as Reactivators of Organophosphonate-Inhibited Eel and Human Acetylcholinesterase in Vitro,” J. Med. Chem. 29 (1986), pp. 2174-2183.
D. Dubus, et al., “Synthese De Diheterocycles En Serie Oxadiazole-1,2,4,” Annales de Chimie (Paris, France) 10 (1975), pp. 331-336.
B. Hedegaard, et al., “Thiophene Chemistry—XIX,” Tetrahedron 27 (1971), pp. 3853-3859.
S.A. Popov, et al., “Synthesis of New Chiral Heterocycles of the Pyrazole and 2-lsoxazoline Types from (+)-3-Carene,” Tetrahedron: Asymmetry vol, 5, No. 3 (1994), pp. 479-489.
S.A. Popov, et al., “Synthesis of 2-Alkyl and 2-Aryl Pyrimidines from β-Chlorovinyl Ketones of Cyclopentanone Type,” Synthetic Commmunications, 31(2), (2001), pp. 233-243.
W. Cocker, et al., “A Convenient Preparation of (−)-β-3,4-Epoxycarane,” Tetrahedron Letters No. 51, (1969), pp. 4451-4452.
S. Lochynski, et al., “Modification of Synthesis of Dihydrochrysanthemolactone from (+)-Car-3-ene,” Journ f. prakt. Chemie. Band 330, Heft 2, (1988), pp. 284-288.
M. Walkowicz, et al., “Uber Stereoisomere 6,6-Dimethyl-Bicyclo-[3.1.0]-Hexanole-3,” Roczniki Chemii Ann. Soc. Chim. Polonorum 41(1967) pp. 927-937.
H. Kuczynski, et al., “0 Krystalicznym (−)-Dwubromo-3,4-Karanie,” Roczniki Chemii Ann. Soc. Chim. Polonorum 38, (1964), pp. 1625-1633.
A.V. Pol, et al., “Oxidation of Δ3-Carene & α-Pinene with Thallium(III) Nitrate,” Indian J. Chem., vol. 19B, (1980) pp. 603-604.
B. Xu, et al., “Acyclic Analogues of Adenosine Bisphophates as P2Y Receptor Antagonists: Phosphate Substitution Leads to Multiple Pathways of Inhibition of Platelet Aggregation,” J. Med. Chem. 45 (2002), pp. 5694-5709.
V.M. Christi, et al., “Einige Valene von Benzanellierten fuenfgliedrigen Hetroarenen-Synthesen und NMR-Spektren,” Angewandte Chemie VCH Verlagsgesellschaft, Weinheim, DE, vol. 102, No. 6 (1990) pp. 704-706.
U.S. Appl. No. 11/993,563, filed Dec. 21, 2008, Actelion Pharmaceuticals Ltd.
U.S. Appl. No. 12/160,520, filed Jul. 10, 2008, Actelion Pharmaceuticals Ltd.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Thiophene derivatives as Sphingosine-1-phosphate-1 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thiophene derivatives as Sphingosine-1-phosphate-1 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiophene derivatives as Sphingosine-1-phosphate-1 receptor... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4057597

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.